Stock Ratings / Health Care / ODTX / forecast

PRME (21) MGTX (27) GLUE (33) CGEM (36) ⌘ Pro Terminal →

Odyssey Therapeutics Inc. (ODTX) 12-Month Stock Forecast & Price Target Cone

$19.83 +1.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.85

Odyssey Therapeutics Inc. (ODTX) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $953.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $19.85 (+0.08%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ODTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY ODTX SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 34% of 52W Range • RSI-14 at 48.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$19.00-9.6% Next Q

Q2 (-2Q)

Grade C-$17.17+14.2% Next Q

Q3 (-1Q)

Grade C$19.60+1.2% Next Q

Current

Grade C-$19.83+0.2% Hist 90D α

Trajectory: C- (51) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ODTX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, ODTX faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($21.79) or 200D SMA ($19.71) invalidates the momentum regime and cuts Target Base ($19.92) toward Bear Floor ($15.54).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ODTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ODTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ODTX Position Size: $10,000

Shares at $19.83: 504.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $15.54

$7,837

$-2,163 (-21.6%)

12M Consensus BaseTarget $19.92

$10,045

+$45 (+0.5%)

12M Bull Case BreakoutTarget $30.50

$15,381

+$5,381 (+53.8%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$21	74%	A
Goldman SachsSector Coverage Lead	BUY	$29	69%	B
JP MorganUS Large-Cap Research	HOLD	$18	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ODTX Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ODTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.77%▲ ASCENDING CHANNEL

2026-10-30O $19.77H $20.20L $19.12C $19.83VOL 166.4K

RES: $35.29SUP: $16.56SMA50: $21.79SMA200: $19.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ODTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ODTX Butterfly Map → + Track ODTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ODTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ODTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ODTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ODTX)

Health Care Rank #215 of 1016 ⚔️ PRME vs ODTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ODTX vs. PRME, MGTX, GLUE, CGEM)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Odyssey Therapeutics Inc. (ODTX) ranks #215 by composite RQD confidence (59/100, grade C-) and #365 by equity capitalization ($953.0M). Within this direct 5-issuer industry benchmark cohort, ODTX leads on earnings valuation at N/A trailing P/E, while PRME leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ODTX ACTIVE Odyssey Therapeutics Inc.	C-	59/100	—	—	—	+1.48%	$953.0M	Benchmark Subject
PRME Prime Medicine Inc.	E	21/100	—	—	-35.0%	-2.24%	$950.4M	/prme-vs-odtx →
MGTX MeiraGTx Holdings plc	E	27/100	—	—	-35.0%	-0.46%	$932.1M	/mgtx-vs-odtx →
GLUE Monte Rosa Therapeutics Inc.	E	33/100	—	—	-35.0%	+0.18%	$927.4M	/glue-vs-odtx →
CGEM Cullinan Therapeutics Inc.	D-	36/100	—	—	-35.0%	-0.71%	$994.3M	/cgem-vs-odtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001882782

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Odyssey Therapeutics Inc. (ODTX) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ODTX closed FY2025 with $269.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$269.8M	—

3. ODTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ODTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Odyssey Therapeutics Inc. (NASDAQ: ODTX) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $19.83 (+1.48% 1D, market cap $953.0M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ODTX ranks #215 in composite RQD confidence.

How does ODTX compare to PRME and MGTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ODTX carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PRME (Prime Medicine Inc.) holds a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M) and MGTX (MeiraGTx Holdings plc) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $932.1M). Among the 5-stock peer group, ODTX leads on earnings multiple (N/A) while PRME leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ODTX?

Per ODTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001882782), Odyssey Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $269.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ODTX trading relative to its 50-day, 200-day, and 52-week technical levels?

ODTX last traded at $19.83 (+1.48% on volume of 212,840 shares), positioning the stock -8.99% below its 50-day simple moving average ($21.79) and +0.61% above its 200-day simple moving average ($19.71). Across its 52-week range of $15.10 to $29.05, ODTX sits at the 33.9% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.35 to $22.31).

ODTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ODTX's 12-month stock price target?

Odyssey Therapeutics Inc. (ODTX) carries a 12-month consensus base price target of $19.92 (+0.5% from $19.83), with a bull-case target of $30.5 and a bear-case floor of $15.54.

Is ODTX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ODTX C- (Hold — HOLD) with an RQD Confidence score of 59/100.

Direct Sub-Reports: ODTX RQD Cockpit ODTX 12M Forecast ODTX Earnings & Move ODTX Dividends & DRIP ODTX Insiders & 13F ODTX Whale Options ODTX Profit Sankey ODTX News & Why